Masao Hagihara

Masao Hagihara

Auto-generated profile, based on publicly available information

Masao Hagihara

Department of Hematology, Eiju General Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Cancer Science
Verified
Journal Article
Open access
SWSatoshi Wakita
Satoshi Wakita
AMAtsushi Marumo
Atsushi Marumo
KMKaoru Morita
Kaoru Morita
SKShinichi Kako
Shinichi Kako
TTTakashi Toya
Takashi Toya
HYHiroki Yamaguchi
Hiroki Yamaguchi
Nucleophosmin1 (NPM1) mutations are the most frequently detected gene mutations in acute myeloid leukemia (AML) and are considered a favorable prognostic factor. We retrospectively analyzed the prognosis of 605 Japanese patients with de novo AML, including 174 patients with NPM1‐mutated AML. Although patients with NPM1‐mutated AML showed a high remission rate, this was not a favorable prognostic factor for overall survival (OS); this is contrary to generally accepted guidelines. Comprehensive gene mutation analysis showed that mutations in codon R882 of DNA methyltransferase 3A (DNMT3AR882 mutations) were a strong predicative factor indicating poor prognosis in all AML (p < 0.0001) and NPM1‐mutated AML cases (p = 0.0020). Furthermore, multivariate analysis of all AML cases showed that DNMT3AR882 mutations and the co‐occurrence of internal tandem duplication in FMS‐like tyrosine kinase 3 (FLT3‐ITD), NPM1 mutations, and DNMT3AR882 mutations (triple mutations) were independent factors predicting a poor prognosis related to OS, with NPM1 mutations being an independent factor for a favorable prognosis (hazard ratios: DNMT3AR882 mutations, 1.946; triple mutations, 1.992, NPM1 mutations, 0.548). Considering the effects of DNMT3AR882 mutations and triple mutations on prognosis and according to the classification of NPM1‐mutated AML into three risk groups based on DNMT3AR882/FLT3‐ITD genotypes, we achieved the improved stratification of prognosis (p < 0.0001). We showed that DNMT3AR882 mutations are an independent factor for poor prognosis; moreover, when confounding factors that include DNMT3AR882 mutations were excluded, NPM1 mutations were a favorable prognostic factor. This revealed that ethnological prognostic discrepancies in NPM1 mutations might be corrected through prognostic stratification based on the DNMT3A status.

15 March 1995 in Cancer
Verified
Journal Article
Open access
TSTatsuo Shimura
Tatsuo Shimura
MHMasao Hagihara
Masao Hagihara
KTKentaro Takebe
Kentaro Takebe
BMBatmunkh Munkhbat
Batmunkh Munkhbat
KOKyoji Ogoshi
Kyoji Ogoshi
KTKimiyoshi Tsuji
Kimiyoshi Tsuji
In NcoI restriction fragment length polymorphism analysis of tumor necrosis factor-beta (TNF-beta) gene, the frequency of 10.5-kb homozygote is low in patients with lung cancer and is associated with a better prognosis. These results should be examined in other malignancies. Using polymerase chain reaction, the authors performed NcoI restriction fragment length polymorphism analysis in 152 patients with gastric cancer, in 69 patients with benign gastric lesion, and in 141 healthy volunteers. In 3-year survival, the 10.5-kb homozygote showed a better prognosis (87.1%) than other alleles (5.5-kb homozygote, 52.5%; heterozygote, 79.1%), and there was a statistically significant difference between the 10.5-kb homozygote and the 5.5-kb homozygote. In 3-year survival for Stages III and IV, the 10.5-kb homozygote also showed a better prognosis (64.9%) than other alleles (5.5-kb homozygote, 16.7%; heterozygote, 41.4%). There were statistically significant differences (10.5-kb homozygote vs. 5.5-kb homozygote, P < 0.01; heterozygote vs. 5.5-kb homozygote, P < 0.05). There was a statistical difference between all patients and Stages III and IV (P < 0.05). The 10.5-kb homozygote of TNF-beta gene is associated with a prolonged survival in patients with gastric cancer, as has been shown in the patients with lung cancer.

1 January 2012 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MHMasao Hagihara
Masao Hagihara
MIMorihiro Inoue
Morihiro Inoue
JHJian Hua
Jian Hua
YIYasunobu Iwaki
Yasunobu Iwaki
Hemophagocytic lymphohistocytosis (HLH) is commonly associated with infectious diseases or T/NK cell-lymphoma; however that with Hodgkin lymphoma (HL) was rarely reported. Herein, we describe a young male diagnosed with lymphocyte-depleted HL (LD-HL) complicated by HLH as an initial manifestation. He was given high-dose steroid therapy plus recombinant thrombomodulin, and subsequent ABVd (doxorubicin, bleomycin, vinblastine, dacarbazine) treatment. In spite of the achievement of a partial remission treated with one cycle of ABVd, he relapsed after 3 cycles. To our knowledge, the present case is very rare, and more intensive treatment might be needed for the long-term control of HLH-complicated HL.

10 August 2010 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
MHMasao Hagihara
Masao Hagihara
JHJian Hua
Jian Hua
MIMorihiro Inoue
Morihiro Inoue
NMNaohiko Michikawa
Naohiko Michikawa

15 October 2018 in Internal Medicine
Verified
Journal Article
Open access
MHMasao Hagihara
Masao Hagihara
TMToru Mese
Toru Mese
SOShin Ohara
Shin Ohara
JHJian Hua
Jian Hua
SIShiro Ide
Shiro Ide
MIMorihiro Inoue
Morihiro Inoue
We herein report a rare case of methotrexate (MTX)-associated intravascular large B-cell lymphoma (IVLBCL) in a man with rheumatoid arthritis. Two episodes of a fever of unknown origin accompanied by elevated levels of serum lactate dehydrogenase and the soluble interleukin-2 receptor occurred within a year, so the patient was suspected of having an MTX-associated lymphoproliferative disorder. His clinical symptoms resolved after the cessation of MTX. However, after treatment with iguratimod, another disease-modified anti-rheumatic drug, markedly similar symptoms recurred, and random skin biopsies resulted in a diagnosis of IVLBCL. The patient received a rituximab-containing chemotherapy and achieved complete remission.

9 March 2022 in Viruses
Verified
Journal Article
Open access
PDF file
DPDavid Pattinson
David Pattinson
PJPeter Jester
Peter Jester
LGLizheng Guan
Lizheng Guan
Seiya YamayoshiSeiya Yamayoshi
Seiya Yamayoshi
SCShiho Chiba
Shiho Chiba
YKYoshihiro Kawaoka
Yoshihiro Kawaoka
Assays using ELISA measurements on serially diluted serum samples have been heavily used to measure serum reactivity to SARS-CoV-2 antigens and are widely used in virology and elsewhere in biology. We test a method using Bayesian hierarchical modelling to reduce the workload of these assays and measure reactivity of SARS-CoV-2 and HCoV antigens to human serum samples collected before and during the COVID-19 pandemic. Inflection titers for SARS-CoV-2 full-length spike protein (S1S2), spike protein receptor-binding domain (RBD), and nucleoprotein (N) inferred from 3 spread-out dilutions correlated with those inferred from 8 consecutive dilutions with an R2 value of 0.97 or higher. We confirm existing findings showing a small proportion of pre-pandemic human serum samples contain cross-reactive antibodies to SARS-CoV-2 S1S2 and N, and that SARS-CoV-2 infection increases serum reactivity to the beta-HCoVs OC43 and HKU1 S1S2. In serial dilution assays, large savings in resources and/or increases in throughput can be achieved by reducing the number of dilutions measured and using Bayesian hierarchical modelling to infer inflection or endpoint titers. We have released software for conducting these types of analysis.